CoChat
Sign Up
Cited by 8Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis

Open access
Dereje, Beyene, Nardos, Aschalew·2023·Journal of Diabetes & Metabolic Disorders
DOI 10.1007/s40200-023-01230-4PMC PMC10638275
Open this paper in CoChat — free accountOpen PDF

Abstract

Background The Dopamine-2 receptor agonists, Bromocriptine and Cabergoline, were originally introduced for prolactinomas, pituitary tumors, and parkinson's disease but have glucose-lowering effects. This paper systematically reviewed the significance of their effects on lowering blood glucose level and conducted a comprehensive systematic search to identify relevant clinical trials of dopamine 2 agonists on glycated hemoglobin (HbA1c) and fasting blood sugar (FBS). Method We conducted a systematic review search in the databases (PubMed, Google Scholar, Cochrane Library, Registers, and Citations) until November 30, 2022, using the PRISMA 2020 statement. The Oxford quality score (Jadad score) was used to assess the study's quality. The present study protocol was registered on the PROSPERO database with ID: CRD42023389582. The study included studies with full abstracts, predefined doses, clear interventions, and blood glucose measurements. Result Data were synthesized from 23 clinical studies that recruited 6125 study subjects. The pooled effect analysis of the clinical trials revealed that dopamine 2 agonists improved HbA1c [SMD = -1.26; 95% CI (-1.60, -0.93), P < .00001], and FBS [SMD = -1.84; 95% CI (-2.61, -1.07), P < .00001]. Each drug's pooled effect analysis indicates bromocriptine significantly improved HbA1c [SMD = -1.25; 95% CI (-1.64, -0.87), P < .00001] and FBS [SMD = -1.90; 95% CI (-2.79, -1.01), P < .00001] and similarly, cabergoline significantly improved HbA1c [SMD = -1.29; 95% CI (-1.96, -0.62), P < .00001] and FBS [SMD = -1.62; 95% CI (-2.82, -0.41), P < .00001]. The pooled and individual analyses demonstrated that dopamine 2 agonists have a significant ability to lower blood glucose levels in clinical studies. Conclusion This study shows that dopamine 2 agonists significantly lowered FBS and HbA1c levels without causing severe negative effects. Even though the results are promising, additional research is necessary to establish the appropriate antihyperglycemic dosage, frequency of daily use, side effects, and potential product interactions when employing dopamine 2 receptor agonists for their antihyperglycemic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40200-023-01230-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. Care D, Suppl SS. Introduction: Standards of medical care in dia- betes -2022. Diabetes Care. 2022;45:2021-2.
  2. Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2022. https:// doi. org/ 10. 3390/ nu140 10166. · DOI
  3. Molinaro R, Dauscher C. Complications resulting from uncon- trolled diabetes. MLO Med Lab Obs. 2017;49:2022.
  4. IDF Diabetes Atlas. International Diabetes Federation. Diabetes Res Clin Pract. 2021. https:// doi. org/ 10. 1016/j. diabr es. 2013. 10. 013. · DOI
  5. Ingle PV, Yin SB, Ying BJ, Leong BK, Xin TZ, Hwa LT, Mun LT. Current trends in pharmacological treatment of type II diabetes mellitus. Int J Pharmacol Res Rev. 2018;7:1-15.
  6. Kumar S, Mittal A, Babu D, Mittal A. Herbal medicines for dia- betes management and its secondary complications. Curr Diabetes Rev. 2021;17:437-56.
  7. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:1-23.
  8. Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic param- eters. Prim Care Diabetes. 2016;10:60-5.
  9. Mahajan R. Bromocriptine mesylate: FDA-approved novel treat- ment for type-2 diabetes. Indian J Pharmacol. 2009;41:197-8.
  10. Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74-80.
  11. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-94.
  12. Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite lev- els in the ventromedial hypothalamus of syrian hamsters. Neu- roendocrinology. 1998;68:1-10.
  13. Byberg S, Futtrup J, Andreassen M, Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect. 2019;8:1395-404.
  14. Schwartz SS, Zangeneh F. Evidence-based practice use of quick- release bromocriptine across the natural history of type 2 diabetes mellitus. Postgrad Med. 2016;128:828-38.
  15. Liang W, Gao L, Li N, et al. Efficacy and safety of Bromocriptine- QR in type 2 diabetes: a systematic review and Meta-analysis. Horm Metab Res. 2015;47:805-12.
  16. Ooi CP, Lye MS. Bromocriptine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018. https:// doi. org/ 10. 1002/ 14651 858. CD010 319. pub2. · DOI
  17. Igata M, Yagi Y, Hanatani S, Sakaguchi M, Ishii N, Yoshinaga K, Kawashima J, Motoshima H, Araki E. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma. J Diabetes Investig. 2021;12:668-71.
  18. Chamarthi B, Gaziano JM, Blonde L, Vinik A, Scranton RE, Ezrokhi M, Rutty D, Cincotta AH. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dys- glycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res. 2015. https:// doi. org/ 10. 1155/ 2015/ 157698. · DOI
  19. Andersen IB, Andreassen M, Krogh J. The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: a systematic review with meta analysis and trial sequential analysis of randomized clinical trials. Diabetes Obes Metab. 2021;23:58-67.
  20. Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, Chowdhury R, Franco OH. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta- analysis in medical research. Eur J Epidemiol. 2020;35:49-60.
  21. Siddaway AP, Wood AM, Hedges LV. How to do a systematic review: a best practice guide for conducting and reporting nar- rative reviews, meta-analyses, and meta-syntheses. Annu Rev Psychol. 2018;70:747-70.
  22. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, Falavigna M. Meta-analysis of prevalence: I(2) sta- tistic and how to deal with heterogeneity. Res Synth Methods. 2022;13:363-7.
  23. Aisbett J, Drinkwater EJ, Quarrie KL, Woodcock S. Applying generalized funnel plots to help design statistical analyses. Stat Pap. 2022. https:// doi. org/ 10. 1007/ s00362-022-01322-y. · DOI
  24. Cochrane Collaboration. Review Manager Web (RevMan Web); 2020.
  25. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18:1-12.
  26. Bahar A, Kashi Z, Daneshpour E, Akha O, Ala S. Effects of caber- goline on blood glucose levels in type 2 diabetic patients. Med (Baltim). 2016;95:e4818.
  27. Barnett H, Chapman C, Gailer K, Hayter CJ. Effect of bromocrip- tine on maturity onset diabetes. Postgrad Med J. 1980;56:11-4.
  28. Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgrad Med. 2016;128:761-9.
  29. Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with met- formin in indian patients with type 2 diabetes mellitus: a rand- omized open labeled phase IV clinical trial. Indian J Pharmacol. 2014;46:24-8.
  30. Kok P, Roelfsema F, Frölich M, Van Pelt J, Stokkel MPM, Mein- ders AE, Pijl H. Activation of dopamine D2 receptors simultane- ously ameliorates various metabolic features of obese women. Am J Physiol -Endocrinol Metab. 2006;291:1038-43.
  31. Krysiak R, Okopien B. Different effects of cabergoline and bro- mocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol. 2015;116:251-6.
  32. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine admin- istration reduces body fat stores in obese subjects and hyperglyce- mia in type II diabetics. Experientia. 1992;48:248-53.
  33. Mejía-Rodríguez O, Herrera-Abarca JE, Ceballos-Reyes G, et al. Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed Res Int. 2013. https:// doi. org/ 10. 1155/ 2013/ 104059. · DOI
  34. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-61.
  35. Taghavi SM, Fatemi SS, Rokni H. Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med J Malaysia. 2012;67:390-2.
  36. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res. 2004;62:55-9.
  37. Chamarthi B, Cincotta AH. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin. Post- grad Med. 2017;129:446-55.
  38. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667-70.
  39. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE. Randomized clinical trial of quick- release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503-8.
  40. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YD. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697-701.
  41. Khalilzade S, Aminorroaya A, Hovsepain S, Amini M. Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients. Adv Biomed Res. 2015;4:253.
  42. Morcos JA, Ebeid AM, Khodeir SA, Elazab GA. Co-administra- tion of Cabergoline and Gliclazide improve glycemic parameters and lipid Profile in T2DM. J Diabetes Metab. 2017. https:// doi. org/ 10. 4172/ 2155-6156. 10007 59. · DOI
  43. Ramteke K, Ramanand S, Ramanand J, Jain S, Raparti G, Pat- wardhan M, Murthy M, Ghanghas R. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endo- crinol Metab. 2011;15:33.
  44. Roe ED, Chamarthi B, Raskin P. Impact of bromocriptine-QR therapy on glycemic control and daily insulin requirement in type 2 diabetes mellitus subjects whose dysglycemia is poorly con- trolled on high-dose insulin: a pilot study. J Diabetes Res. 2015. https:// doi. org/ 10. 1155/ 2015/ 834903. · DOI
  45. Tell SS, Schafer M, Vigers T, Baumgartner AD, Lyon E, Gross S, Polsky S, Snell-Bergeon JK, Schauer IE, Nadeau KJ. Bromocrip- tine quick-release as adjunct therapy in youth and adults with type 1 diabetes: a randomized, placebo-controlled crossover study. Dia- betes Obes Metab. 2022;24:2148-58.
  46. Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM. Effect of Bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931-43.
  47. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the arrive guidelines for reporting animal research. PLoS Biol. 2010;8:6-10.
  48. Winzap P, Davies A, Klingenberg R, et al. Diabetes and baseline glucose are associated with inflammation, left ventricular func- tion and short-and long-term outcome in acute coronary syn- dromes: role of the novel biomarker Cyr 61. Cardiovasc Diabetol. 2019;18:1-10.
  49. Berard LD, Siemens R, Woo V. Monitoring glycemic control. Can J Diabetes. 2018;42:47-S53.
  50. Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperpro- lactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14:259-65.
  51. Mikhail N. Quick-release bromocriptine for treatment of type 2 diabetes. Curr Drug Deliv. 2011;8:511-6.

Cited by

Sorted by citations

Authors
Dereje, B., & Nardos, A.
Affiliations
Hawassa University (ET)
ORCID
Venue
Journal of Diabetes & Metabolic Disorders
Publisher
Springer Science and Business Media LLC
Published
2023-05-12
Volume
22
Issue
2
Pages
931-943
ISSN
2251-6581 (ISSN-L)
DOI
10.1007/s40200-023-01230-4
PMC
PMC10638275
OpenAlex
W4376255617
Cited by
8
References
3
Citations by year
2025: 2 · 2024: 5 · 2023: 1
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Diabetes & Metabolic Disorders (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, bromocriptine, cabergoline, HbA1c, fasting blood glucose, glucose-lowering effect, antidiabetic efficacy, prolactinoma, Parkinson's disease, pituitary tumors, off-label drug use, insulin secretion, insulin sensitivity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review